Solta Medical Announces FDA 510(k) Clearance of New Fraxel re:store(R) Dual La...( HAYWARD Calif. Oct. 14 /- Solta Medic...),Health

HAYWARD, Calif., Oct. 14 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (Nasdaq: SLTM), the pioneer in fractional resurfacing and market leader of aesthetic skin treatments, today announced it has received FDA 510(k) clearance for the new Fraxel re:store Dual laser system. The Fraxel re:store Dual system takes the industry leading fractional laser technology to the next level by adding a novel 1927 nm wavelength, the first ever application of a Thulium laser in the aesthetics market. The new Fraxel re:store Dual system is optimized for both on face and large body areas to address clearance of pigmentation and other superficial skin conditions all in a single treatment.

Prior to the non-ablative Fraxel re:store Dual system, laser skin resurfacing procedures were largely limited to the face. The expanded versatility of the Fraxel re:store Dual system, with the addition of the new 1927 nm wavelength, increases the areas of the body that physicians can treat and further demonstrates Solta's dedication to producing the safest and most effective aesthetic energy devices in the industry.

"Solta Medical is committed to developing innovative, safe, and effective anti-aging solutions that deliver superior results for patients with the most advanced aesthetic treatments available today," said Stephen J. Fanning, Chairman of the Board, President and CEO of Solta Medical, Inc. "Treatments with new Fraxel re:store Dual system result in smoother, fresher looking skin with less downtime as compared to ablative treatment options. In addition, physicians are now able to treat multiple body areas in one treatment session."

The new Fraxel re:store Dual system provides significant enhancements that enable physicians to better address pigmentation and other dyschromia on the entire body. Fraxel re:store Du
'/>"/>